Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

CONCLUSIONS: Benralizumab was noninferior to mepolizumab for the induction of remission in patients with relapsing or refractory EGPA. (Funded by AstraZeneca; MANDARA ClinicalTrials.gov number, …